VITA BALANCE INC. – Trademark Portfolio
Entity Type: 03
VITA BALANCE INC. holds 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 23 trademarks are registered. Notable registered marks include ANAVOX, CILEXIN, FOLEXIN, LUTENOL, and OPTIVET. The owner is based in RICHMOND, VA.
7400 BEAUFONT SPRINGS DR., STE. 300
RICHMOND, VA 23225
Showing of trademarks Trademarks
Trademark Classifications
VITA BALANCE INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does VITA BALANCE INC. have?
VITA BALANCE INC. has 28 U.S. trademarks filed with the USPTO. Of these, 23 registered, 5 abandoned.
What trademark classes does VITA BALANCE INC. file in?
VITA BALANCE INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are VITA BALANCE INC.'s most well-known trademarks?
VITA BALANCE INC.'s registered trademark portfolio includes well-known marks such as ANAVOX, CILEXIN, FOLEXIN, LUTENOL, and OPTIVET. These are among 23 currently registered trademarks in the portfolio.
What is VITA BALANCE INC.'s trademark registration success rate?
VITA BALANCE INC. has a 82% trademark registration rate, with 23 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.